Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cerus, a biomedical products company, has signed an agreement to extend its manufacturing agreement with Fenwal, a provider of blood technologies, for Intercept blood system products.
Subscribe to our email newsletter
Under the new agreement, Fenwal will supply Cerus with finished disposable kits for the Intercept platelet and plasma systems through the end of 2013.
Claes Glassell, president and CEO of Cerus, said: “We are pleased to have extended our supply relationship with Fenwal. The new agreement is expected to assure our long-term supply of finished Intercept platelet and plasma kits while reducing our unit costs.
“Together with other initiatives, we believe we are making good progress toward meeting our objective of extending our cash resources through the end of 2009.”